

*Contact Person:* Jay Joshi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7846, Bethesda, MD 20892, (301) 435-1184, [joshij@csr.nih.gov](mailto:joshij@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Brain Disorders and Clinical Neuroscience-Members.

*Date:* July 19, 2007.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Jay Joshi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7846, Bethesda, MD 20892, (301) 435-1184, [joshij@csr.nih.gov](mailto:joshij@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Xenopus Genetics and Genomics.

*Date:* July 23-24, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Barbara J. Thomas, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2218, MSC 7890, (301) 435-0603, [bthomas@csr.nih.gov](mailto:bthomas@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Small Business: Arthritis, Connective Tissue and Skin Sciences.

*Date:* July 23, 2007.

*Time:* 8 a.m. to 12 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Watergate Hotel, 2650 Virginia Avenue, NW., Washington, DC 20037.

*Contact Person:* Harold M. Davidson, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD 20892, (301) 435-1776, [davidsoh@csr.nih.gov](mailto:davidsoh@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Stem Cells, Neuron Migration and Guidance.

*Date:* July 23, 2007.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Carol Hamelink, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5040H, MSC 7850, Bethesda, MD 20892, (301) 451-1328, [hamelinc@csr.nih.gov](mailto:hamelinc@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Small Business: Digestive Sciences and Bioengineering.

*Date:* July 23, 2007.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Bonnie L. Burgess-Beusse, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2191C, MSC 7818, Bethesda, MD 20892, (301) 435-1783, [beusseb@mail.nih.gov](mailto:beusseb@mail.nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.847-93.878, 93.892, 93.893, National Institutes of Health, HHS)

*Dated:* June 12, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3014 Filed 6-19-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Anti-Mesothelin Antibodies Useful for Immunological Assays

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/681,104, filed May 12, 2005, entitled "Anti-Mesothelin Antibodies Useful For Immunological Assays" [E-015-2005/0-US-01] and PCT Application No. PCT/US2006/018502, filed May 11, 2006, entitled "Anti-Mesothelin Antibodies Useful For Immunological Assays" [E-015-2005/0-PCT-02] to Cambridge Antibody Technology, Ltd., which has offices in Cambridge, United Kingdom. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of the SSIP immunoconjugate and variants thereof for the treatment of mesothelin expressing cancers.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of

Technology Transfer on or before August 20, 2007 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jesse S. Kindra, J.D., M.S., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5559; Facsimile: (301) 402-0220; E-mail: [kindraj@mail.nih.gov](mailto:kindraj@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** This technology relates to anti-mesothelin antibodies with a particularly high affinity for mesothelin and the ability to be used in immunological assays for detecting the presence of mesothelin in biological samples. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

*Dated:* June 11, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-11828 Filed 6-19-07; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### The Critical Infrastructure Partnership Advisory Council (CIPAC)

**AGENCY:** Directorate for National Protection and Programs, DHS.

**ACTION:** Committee management; update on CIPAC committee membership.

**SUMMARY:** The Department of Homeland Security announced the establishment of the Critical Infrastructure Partnership Advisory Council (CIPAC) by Notice published in the **Federal Register** on March 24, 2006 ("First CIPAC Notice"). That Notice identified the purpose of the committee as well as its membership. This Notice provides the quarterly update including instructions on how the public can obtain the most current roster of CIPAC membership.

**FOR FURTHER INFORMATION CONTACT:** Brett Lambo, Partnership and Outreach Division, Office of Infrastructure Protection, National Protection and Programs Directorate, United States Department of Homeland Security, Washington, DC 20528, telephone (703) 235-5311 or via e-mail at [brett.lambo@dhs.gov](mailto:brett.lambo@dhs.gov).

*Responsible DHS Official:* Nancy J. Wong, Director Infrastructure Programs Office, Partnership and Outreach Division, Office of Infrastructure Protection, National Protection and Programs Directorate, United States Department of Homeland Security, Washington, DC 20528, telephone (703) 235-5349.

**SUPPLEMENTARY INFORMATION:** The CIPAC is intended to facilitate interaction between representatives of government and the community of critical infrastructure and key resources (CI/KR) owners and operators in each critical sector. As set forth in the CIPAC's originating documents, it engages in: "Planning; coordination; security program implementation; operational activities related to critical infrastructure protection security measures, including incident response, recovery, and reconstitution from events both man-made and naturally occurring; and the sharing of information about threats, vulnerabilities, protective measures, best practices, and lessons learned."

CIPAC is designed to include as many of the owners and/or operators and the owner and/or operator representative trade associations deemed by each sector's Sector Coordinating Council (SCC) as necessary as participants in these activities. CIPAC Membership is comprised of the CI/KR owner and/or operator entities (and the trade associations that represent CI/KR owners and/or operators) which the Department of Homeland Security (DHS) in conjunction with the Sector Specific Agency (SSA) (when different than DHS) recognizes as members of that sector's Sector Coordinating Council (SCC). It also includes Federal, State, local, and tribal government agencies (or their representative bodies)

that comprise the membership of the Government Coordinating Council (GCC) for each sector as recognized by DHS in conjunction with the Sector Specific Agency (SSA).

Owners and/or operators or trade associations representing the interests of owners and/or operators that own and invest in infrastructure assets, in the systems and processes to secure them, and that are held responsible by the public for their operations and the response and their recovery when their infrastructures or key resources are disrupted.

This Notice serves as a quarterly notice to provide instructions for obtaining the most current roster of CIPAC membership. The most recent membership roster is published on the CIPAC Web site (<http://www.dhs.gov/cipac>). The CIPAC Web site maintains an updated list of all Sector industry/institutional CIPAC membership and all government entities involved in CIPAC. Any member of the public may visit the Web site to learn about CIPAC membership, and find a list of meetings and agendas.

This Notice also serves to announce the first annual Plenary Meeting of the CIPAC to be held on July 19, 2007 in the Washington, DC Metropolitan area. The meeting will be open to the public. The CIPAC Web site noted above will provide details of the meeting as they become available.

Dated: June 12, 2007.

**Nancy J. Wong,**

*Director, Infrastructure Programs Office, CI/KR Partnership and Outreach Division, United States Department of Homeland Security.*

[FR Doc. E7-11840 Filed 6-19-07; 8:45 am]

**BILLING CODE 4410-10-P**

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Federal Emergency Management Agency, DHS.

**ACTION:** Notice and request for comments.

**SUMMARY:** The Federal Emergency Management Agency (FEMA) has submitted the following information collection to the Office of Management and Budget (OMB) for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission

describes the nature of the information collection, the categories of respondents, the estimated burden (*i.e.*, the time, effort and resources used by respondents to respond) and cost, and includes the actual data collection instruments FEMA will use.

*Title:* The National Flood Insurance Program Biennial Report.

*OMB Number:* 1660-0003.

*Abstract:* The National Flood Insurance Program (NFIP) Biennial Report enables FEMA to meet its regulatory requirement under 44 CFR 59.22(b)(2). It also enables FEMA to be more responsive to the ongoing changes that occur in each participating community's flood hazard area. These changes include, but are not limited to, new corporate boundaries, changes in flood hazard areas, new floodplain management measures, and changes in rate of floodplain development. It is also used to evaluate the effectiveness of the community's floodplain management activities. The evaluation is accomplished by analyzing information provided by the community, such as the number of variances and floodplain permits granted by each community in relationship to other information contained in the Biennial Report as well as other data available in FEMA's Community Information System (CIS). The Biennial Report also provides an opportunity for NFIP participating communities to request technical assistance in implementing a floodplain management program. FEMA regional offices use this information as a means to know which communities need support and guidance.

The NFIP Biennial Report is also one of the tools used to assist FEMA in meeting its requirement under section 575 of the National Flood Insurance Reform Act. A "yes" answer to Item A-D in Section I of the report will provide the basis for FEMA to follow-up by contacting the community for clarification and/or elaboration regarding changes and activities occurring in a community's flood hazard area. This information will be used in ranking and prioritizing one community's mapping needs against all other communities in the NFIP and for determining how the limited flood hazard mapping funds are allocated for map updates.

*Affected Public:* State, local or tribal governments, farms, individuals or households, business or other for-profit, not-for-profit institutions representing the estimated 20,500 United States and United States territorial communities that are participating members of the NFIP. The NFIP requires that communities participating in the NFIP